- recruitingPHASE3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study is for people with a type of cancer called GEP-NETs that has grown after previous treatment. It tests a new medicine, RYZ101, against standard treatments to see if it is safe and works better in stopping the cancer's growth.
United States · Belgium · Brazil - active not recruiting
DOTATOC PET/CT for Imaging NET Patients
This study looks at a new type of scan called 68Ga-DOTATOC PET/CT for checking on neuroendocrine tumours (NETs) and similar growths. It compares it to a standard scan to see if it’s better at finding these conditions safely.
Canada - active not recruitingPHASE3
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
This study compares a new radiation treatment (177Lu-edotreotide PRRT) with a standard drug (Everolimus) for people with certain types of advanced neuroendocrine tumours that affect the gut or pancreas. It aims to see which treatment works better and is safer.
United States · Australia · Austria - recruiting
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
This study looks at how a medicine called cabozantinib works for people with neuroendocrine tumours (NETs). Participants have already tried other treatments. Doctors will collect information from their regular hospital visits to see how well the medicine works and if there are any side effects.
Austria · Germany - not yet recruitingPHASE2
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
This study looks at using heat treatment (hyperthermia) with repeat radiation therapy for certain cancers that have come back after earlier radiation. It checks if this combined approach works as well as the first treatment for preventing the cancer from returning locally.
Germany - recruitingPHASE2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
This study looks at giving more doses of Lutathera to people with a certain type of gut cancer that has started to grow again. It aims to see if two extra doses are better than just watching the cancer closely.
France - active not recruitingPHASE2
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
This study looks at a new combination of existing medicines for a type of neuroendocrine tumour that has spread and hasn't been treated with chemotherapy before. It aims to see if combining pembrolizumab with chemotherapy, followed by a maintenance treatment, is safe and effective.
United Kingdom - active not recruiting
Post-Authorization Long-Term Safety Study of LUTATHERA
This study looks at the long-term safety of a treatment called LUTATHERA for a type of cancer called neuroendocrine tumours. Researchers want to understand any side effects that might appear over time in patients who have received this medicine.
United States · France · Portugal - active not recruitingPHASE3
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
This study looks at a new type of radiation treatment called PRRT (using Lutetium-177) for certain aggressive bowel and pancreas neuroendocrine tumours. It compares this new treatment with standard care to see if it's more effective, safer, and improves patients' quality of life.
United States · Australia · China - recruitingPHASE1
Lutathera and ASTX727 in Neuroendocrine Tumours
This study looks at a new way to treat neuroendocrine tumours. It checks if taking a medicine called ASTX727 before Lutathera helps Lutathera work better. Doctors will use special scans to see if this combination treatment improves how your body responds.
United Kingdom - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium